CRSP Earnings & Financial Statements
CRISPR Therapeutics AG
$51.27
+$1.05(+2.09%)
40
Overall
60
Value
10
Tech
50
Quality
Market Cap
$4.86B
Volume
622.26K
52W Range
$44.12 - $75.16
Target Price
$85.00
CRSP earnings and financial statements: CRISPR Therapeutics AG's income statement, balance sheet and cash flow statement, annual and quarterly.
CRSP Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.51M | $37.31M | $371.21M | $436.0K | $914.96M |
| Cost of revenue | - | $110.25M | $130.25M | $110.25M | $101.18M |
| Operating income | -$664.57M | -$466.57M | -$222.54M | -$673.16M | $373.53M |
| EBITDA | -$558.49M | -$343.41M | -$130.88M | -$626.33M | $391.48M |
| Net income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | $377.66M |
| EPS (diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B |
| Total liabilities | $343.43M | $309.95M | $346.77M | $367.58M | $352.42M |
| Shareholders’ equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B |
| Cash and equivalents | $347.60M | $298.30M | $389.50M | $211.90M | $923.00M |
| Long-term debt | $188.17M | $206.41M | $223.01M | $228.18M | $212.87M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M |
| Capital expenditure | -$914.0K | -$1.90M | -$11.97M | -$37.19M | -$81.70M |
| Free cash flow | -$345.93M | -$144.68M | -$269.85M | -$532.93M | $457.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRSP | $51.27 | +2.1% | 622.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |